Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem's Q1 Revenues Dip 1 Percent

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Monday that its first-quarter revenues declined 1 percent year over year as a decline in product revenues was offset by growth for its clinical lab services.

The New York-based provider of research products and molecular biology reagents brought in total revenues of $25.6 million for the three months ended Oct. 31, compared to $25.8 million for the first quarter of Fiscal Year 2012. Its product revenues fell to $8.4 million from $9.7 million, while its clinical lab sales jumped to $15.2 million from $14.2 million. Royalty and license fee income was $2 million versus $1.9 million.

The firm noted that its clinical lab business was negatively impacted by around $700,000 due to Hurricane Sandy, which resulted in sharply diminished specimen counts over the last three days of the quarter.

Enzo posted a net loss of $3.7 million, or $.09 per share, for the quarter, compared to a net loss of $4.5 million, or $.12 per share, for the first quarter of FY 2012.

"We are making noteworthy progress and have yet to fully benefit from the anticipated $6 million in annual cost savings that will result from last year's realignment," Enzo President Barry Weiner said in a statement. "We anticipate that new products, operating efficiencies, enhanced marketing efforts and improved cash utilization will drive stronger operating results as the year develops."

The firm announced during its fourth-quarter conference call in October that it would realign its operations with the aim of reducing its cash burn.

Enzo finished the quarter with $13.4 million in cash, cash equivalents, and short-term investments. It also held working capital of $18.3 million.

Subsequent to the end of its first quarter, Enzo won a patent infringement case against Life Technologies. The jury in that case awarded Enzo $48.6 million in damages, though Life Tech intends to appeal the decision.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.